Back to Search
Start Over
Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.
- Source :
-
BMC infectious diseases [BMC Infect Dis] 2024 Aug 22; Vol. 24 (1), pp. 852. Date of Electronic Publication: 2024 Aug 22. - Publication Year :
- 2024
-
Abstract
- Background: To evaluate the demographic, clinical, and prognostic characteristics of patients diagnosed with COVID-19-associated mucormycosis (CAM) in Iranian patients.<br />Methods: This prospective observational study was conducted in 8 tertiary referral ophthalmology centers in different provinces of Iran during the fifth wave of the COVID-19 pandemic. All patients were subjected to complete history taking and comprehensive ophthalmological examination and underwent standard accepted treatment strategy based on the disease stage.<br />Results: Two hundred seventy-four CAM patients (most were males (150, 54.7%)) with a mean age of 56.8 ± 12.44 years were enrolled. Patients with a history of cigarette smoking (Adjusted Odds Ratio (AOR) = 4.36), Intensive Care Unit admission (ICU) (AOR = 16.26), higher stage of CAM (AOR = 2.72), and receiving endoscopic debridement and transcutaneous retrobulbar amphotericin B (AOR = 3.30) had higher odds of mortality. History of taking systemic corticosteroids during COVID-19 was significantly associated with reduced odds of mortality (AOR = 0.16). Generalized Estimating Equations analysis showed that the visual acuity of deceased patients (LogMAR: 3.71, 95% CI: 3.04-4.38) was worse than that of patients who were discharged from the hospital (LogMAR: 2.42, 95% CI: 2.16-2.68) (P < 0.001).<br />Conclusions: This study highlights significant risk factors for mortality in patients with CAM, such as cigarette smoking, ICU admission, advanced CAM stages, receiving transcutaneous retrobulbar amphotericin B and worser visual acuity. Conversely, a history of systemic corticosteroid use during COVID-19 was linked to reduced mortality. These findings underscore the critical need for early identification and targeted interventions for high-risk CAM patients to improve clinical outcomes.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Middle Aged
Iran epidemiology
Female
Risk Factors
Prospective Studies
Aged
Adult
Antifungal Agents therapeutic use
Intensive Care Units statistics & numerical data
Amphotericin B therapeutic use
Debridement
COVID-19 complications
COVID-19 mortality
COVID-19 epidemiology
Mucormycosis epidemiology
Mucormycosis mortality
Mucormycosis drug therapy
Mucormycosis complications
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2334
- Volume :
- 24
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 39174954
- Full Text :
- https://doi.org/10.1186/s12879-024-09755-6